DM005

DM005 is a bispecific antibody-drug conjugate (ADC) designed to treat advanced solid tumors by simultaneously targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (c-MET). Developed using fully human antibodies with a common light chain from the Biocytogen RenLite platform, DM005 combines high binding avidity and efficient tumor cell internalization. The ADC utilizes BLD1102 as its linker-payload—a novel topoisomerase 1 inhibitor—enabling potent cytotoxic activity against tumor cells while minimizing off-target toxicity. Preclinical studies have demonstrated robust antitumor efficacy in both cell-derived and patient-derived xenograft models of non-small cell lung cancer and other EGFR/c-MET co-expressing tumors. The drug is currently in Phase 1 clinical trials for various advanced solid malignancies, including non-small cell lung cancer, head and neck cancer, squamous cell carcinoma, and gastrointestinal cancers[1][3][4][5][6][7].